BioCryst Pharmaceuticals (BCRX)

Executive Summary

BioCryst Pharmaceuticals is a commercial-stage biotech focused on oral small-molecule therapies for rare diseases, primarily hereditary angioedema (HAE) with its approved product Orladeyo (berotralstat). The company leverages a structure-guided drug design platform to develop first-in-class or best-in-class treatments. In 2024, BioCryst generated significant revenue from Orladeyo and is advancing pipeline programs, including BCX10013 for paroxysmal nocturnal hemoglobinuria (PNH) and BCX9930 for complement-mediated diseases. The company's strong commercial base and disciplined R&D strategy position it for sustained growth, though near-term dependence on Orladeyo and pipeline execution risks temper conviction.

Upcoming Catalysts (preview)

• Q3 2026BCX10013 Phase 2 data readout in PNH55% success
• Q4 2026Orladeyo label expansion for pediatric HAE patients75% success
• Q1 2027Full-year 2026 revenue guidance update90% success